Image

A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy

Recruiting
19 years of age
Both
Phase 1

Powered by AI

Overview

This is an Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients with Advanced Cancer Failed to Standard Therapy

Description

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IMC-002.

Multiple-dose levels of IMC-002 will be tested in subjects with advanced cancer.

Eligibility

Inclusion Criteria:

  1. Signed ICF
  2. Histologically or cytologically proven metastatic or locally advanced solid tumors
  3. Subject must have at least 1 measurable lesion by RECIST 1.1.
  4. Availability of tumor archival material or fresh biopsies
  5. Adequate hematologic function, hepatic function, and renal function
  6. Agree to use effective contraception
  7. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion Criteria:

  1. Treatment with nonpermitted drugs
  2. Prior treatment with a CD47 or SIRPĪ± targeting agent
  3. Concurrent anticancer treatments
  4. Major surgery or significant traumatic injury prior to Screening or planned major surgery during the study period
  5. Previous malignant disease other than the target malignancy for this study
  6. Active infection requiring systemic therapy before Day 1
  7. Any active autoimmune disease, or history of autoimmune disease
  8. Any psychiatric or cognitive condition
  9. Known severe hypersensitivity reaction
  10. Pregnant or lactating
  11. Currently enrolled in another clinical study

Study details

Advanced Cancer

NCT05276310

ImmuneOncia Therapeutics Inc.

25 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.